In 2004 three groups demonstrated the EGFR TK domain mutations in NSCLC and showed a striking correlation between the gefitinib sensitivity and TK domain mutations (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004). This evidence concerns the gene TKT and non-small cell lung carcinoma.